- PURINES AND METHODS OF THEIR USE
-
Disclosed are compounds useful in the treatment of neurological disorders. The compounds described herein, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological diseases.
- -
-
Page/Page column 72
(2021/12/28)
-
- PYRROLOPYRIMIDINE ITK INHIBITORS
-
Disclosed herein are arylpyridinone compounds and compositions useful in the treatment of ITK mediated diseases, such as inflammation, having the structures of Formulas (I)-(IV): wherein the R groups, m, n, and X are as defined in the detailed description. Methods of inhibition of ITK activity in a human or animal subject are also provided.
- -
-
Paragraph 0427; 0428
(2020/02/27)
-
- COMPOUNDS USEFUL AS KINASE INHIBITORS
-
This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK).The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.
- -
-
Paragraph 00433
(2017/07/14)
-
- HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS AND COMBINATIONS THEREOF
-
Heterocyclic modulators of lipid synthesis are provided as well as pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds; and methods of treating conditions characterized by disregulation of a fatty acid synthase pathway by the administration of such compounds and combinations of such compounds and other therapeutic agents.
- -
-
Page/Page column 310
(2015/07/07)
-
- New Enzyme Inhibitor Compounds
-
Disclosed are compounds which inhibit SSAO enzyme activity. Also disclosed are pharmaceutical compositions comprising these compounds and the use of these compounds in the treatment or prevention of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases, immune disorders and the inhibition of tumour growth.
- -
-
Paragraph 0253; 0254
(2013/05/08)
-
- NEW ENZYME INHIBITOR COMPOUNDS
-
Compounds of formula (I) are inhibitors of Semicarbazide-sensitive amine oxidase wherein R1, A, X and R2 are as defined in the claims.
- -
-
Page/Page column 54
(2011/10/10)
-
- Pyrazolo-[1,5-a]-1,3,5-triazine corticotropin-releasing factor (CRF) receptor ligands
-
The syntheses and rat CRF receptor binding affinities of 'retro-pyrazolotriazine' corticotropin-releasing factor (CRF) ligands 4 are reported. Some have high affinity for rat CRF receptors (Ki≤10 nM). The data provide additional support for the hypothesis that it is possible to interchange isosteric cores with similar electronic properties in the design of high-affinity CRF receptor ligands, provided the peripheral pharmacophore elements are maintained in the same three-dimensional array.
- Gilligan, Paul J.,Folmer, Beverly K.,Hartz, Richard A.,Koch, Stephanie,Nanda, Kausik K.,Andreuski, Stephen,Fitzgerald, Lawrence,Miller, Keith,Marshall, William J.
-
p. 4093 - 4102
(2007/10/03)
-